Flutamide Tablets

This product is a non-steroidal androgen antagonist that competes with androgens for androgen receptors in tumor sites, blocks cell uptake of androgens, and inhibits the binding of androgens to target organs. After binding to androgen receptors, this product forms a receptor complex, enters the cell nucleus, and binds to nuclear proteins, thereby inhibiting tumor cell growth.

The chemical name of this product is: 2-dimethyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide.

This product is a light yellow tablet

It is suitable for prostate cancer and is effective for both first-time and retreatment patients.

250 mg each time, orally, 3 times a day.

Male breasts become feminized, breast tenderness, sometimes accompanied by galactorrhea, which can disappear if the dose is reduced or the drug is stopped. A few patients may experience diarrhea, nausea, vomiting, increased appetite, insomnia and fatigue. Rarely, there may be decreased libido, transient liver function abnormalities and decreased sperm count. This product has less potential cardiovascular effects than diethylstilbestrol.

It is contraindicated for those who are allergic to this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Not yet clear.

Store in a light-proof, sealed and dry place.

250 mg/tablet

24 months.